논문/저서

3. https://www.ncbi.nlm.nih.gov/myncbi/1NqAvzcdnmpQw/bibliography/public/
   

4. 
   

5. <대표논문>
   

6. Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR. 

7. J Thorac Oncol. 2023 Aug;18(8):1042-1054.

8. 
   

9. Dual Impact of IGF2 on Alveolar Stem Cell Function during Tobacco-Induced Injury Repair and Development of Pulmonary Emphysema and Cancer. 

10. Cancer Res. 2023 Jun 2;83(11):1782-1799.

11. 
    

12. Novel antitumor therapeutic strategy using CD4+ T cell-derived extracellular vesicles. 

13. Biomaterials. 2022 Oct;289:121765.
    

14. 
    

15. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.

16. Arch Pharm Res. 2022 Apr;45(4):263-279.

17. 
    

18. CD5L as an Extracellular Vesicle-Derived Biomarker for Liquid Biopsy of Lung Cancer. 

19. Diagnostics (Basel). 2021;11(4):620.

20. 
    

21. p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. 

22. Cell Rep. 2019 Aug 13;28(7):1860-1878.
    

23. 
    

24. Glucose Transporter 1 Gene Variants Predict the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer.

    Annals of surgical oncology. 2018; 25(11):3396-3403.

25. 
    

26. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.

    Nature communications. 2017; 8:15503.

27. 
    

28. Genetic polymorphisms in glycolytic pathway are associated with the prognosis of patients with early stage non-small cell lung cancer.

    Scientific reports. 2016; 6:35603.

29. 
    

30. Polymorphisms in cancer-related pathway genes and lung cancer.

    The European respiratory journal. 2016; 48(4):1184-1191.

31. 
    

32. PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.

    Scientific reports. 2016; 6:25952.

33. 
    

34. A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology. 2015; 26(6):1142-8.

35. 
    

36. The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations.

    Molecular carcinogenesis. 2015; 54(2):93-101.

37. 
    

38. A functional polymorphism in CSF1R gene is a novel susceptibility marker for lung cancer among never-smoking females.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014; 9(11):1647-55.

39. 
    

40. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.

    Lung cancer (Amsterdam, Netherlands). 2013; 82(2):330-9.

41. 
    

42. Replication of results of genome-wide association studies on lung cancer susceptibility loci in a Korean population.

    Respirology (Carlton, Vic.). 2012; 17(4):699-706.

43. 
    

44. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010; 5(11):1734-40.